Rallybio Mails Final Proxy for Nov 4 Vote on Avenzo Reverse Merger
RLYB has more than doubled off its 52-week low of $3.67 on light trading volume (0.2× avg).
Summary
Rallybio mailed the final proxy for its November 4, 2026 shareholder vote on the Avenzo reverse merger, which would leave existing Rallybio holders with roughly 2.8% of the combined company plus a cash distribution of substantially all of its ~$82.2M net cash and contingent value rights.
Key Events · M&A and Partnerships · RLYB
-
Final Proxy Mailed for Avenzo Merger Vote
Definitive proxy/prospectus dated October 15, 2026 sets the Rallybio annual meeting for November 4, 2026, where holders vote on the Avenzo reverse merger and related proposals.
-
Existing Holders Left With ~2.8% of Combined Company
Post-closing, Avenzo pre-merger holders are expected to own ~56.6%, Concurrent Financing investors ~40.6%, and Rallybio's pre-merger holders only ~2.8% on a fully diluted basis.
-
Cash Distribution and CVRs as Consideration
Rallybio intends to distribute substantially all of its ~$82.2M net cash (as of August 15, 2026) to pre-closing stockholders, capped at $50M before the meeting, plus one CVR per share tied to legacy-asset proceeds through December 31, 2031.
-
Reverse Split and Name Change Also on Ballot
Proposals include a 1-for-2 to 1-for-9 reverse split, a name change to Avenzo Therapeutics, and an authorized-share increase from 200M to 500M; the share issuance, reverse split and name change are conditions to closing.
Analysis · RLYB · Life Sciences
This is the definitive proxy/prospectus for the Avenzo reverse merger, first mailed to stockholders on October 15, 2026, and it sets the November 4, 2026 annual meeting where holders vote on the deal. The economics are unchanged from the S-4 amendments: Avenzo holders get ~56.6% of the combined company, Concurrent Financing investors ~40.6%, and Rallybio's pre-merger holders just ~2.8% — a near-total loss of ownership for existing Rallybio shareholders, who are compensated mainly by a cash distribution of substantially all of Rallybio's ~$82.2M net cash plus contingent value rights on the legacy assets. Approval of the share issuance, reverse split (1-for-2 to 1-for-9) and name change are conditions to closing, and the combined company is expected to trade as 'AVZO'. The vote is the binary event: if the proposals fail, the merger does not close and Rallybio faces a standalone future it has already concluded is not viable without a financing it could not complete.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 36.7% of the 962 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $16.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $89.1M. The 52-week trading range was $3.67 to $17.57. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.